Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble?

Abbott’s $23 billion acquisition of Exact Sciences positions the company to become a major player in cancer diagnostics. Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions remain about long-term growth amid rising competition and the challenges of integrating a patient-focused, tech-heavy business. The…

Read More

The Opportunity being Missed in UK Healthcare Buyouts

Following Brexit, the funding infrastructure for new buyout funds in the UK has broken down. These new managers are now struggling to find anchor investors and offer an opportunity to the private sector to step in and secure attractive returns. The post The Opportunity being Missed in UK Healthcare Buyouts appeared first on MedCity News.

Read More